Effects of 16-week Bikram yoga program on heart rate variability and cardiovascular disease risk factors in sedentary, stressed adults.

Not Applicable

Completed

• Conditions: Stress; Cardiovascular disease; Obesity; Alternative and Complementary Medicine - Other alternative and complementary medicine; Mental Health - Other mental health disorders; Cardiovascular - Other cardiovascular diseases

• Registration Number: ACTRN12616000867493
• Lead Sponsor: Miss Zoe Hewett

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-07-04
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 68

Inclusion Criteria

Adult (>18 years); sedentary (<150min of continuous moderate-intensity exercise per week for at least 6 months); a score >7 on the stress component of the 21-item depression-anxiety-stress scale (DASS-21); waist circumference as a risk factor greater than 80cm (women) and greater than 94cm (men), able to attend 3-5 Bikram yoga classes per week for 16 weeks; no acute or chronic medical conditions which would make Bikram yoga potentially hazardous or primary outcomes impossible to assess (according to ACSM risk stratification guidelines); ability to communicate in English; willingness and cognitive ability to provide written informed consent to participate in the trial; access to internet and email.

Exclusion Criteria

Currently active; participation in Bikram yoga in the last 6 months or at any point consistently for >2 years; diagnosed chronic diseases (cardiovascular disease, blood pressure >140/90, uncontrolled diabetes or hyperlipidaemia); pregnancy; pacemaker.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
High frequency heart rate variability (HF HRV).HF HRV was assessed using ECG data produced by the SphygmoCor equipment and software (SphygmoCor, AtCor Medical Pty, Sydney, Australia).[Baseline (week 0) and after the 16-week intervention at completion (week 17)]